Resource Center: buprenorphine

This is the American Society of Addiction Medicine's member directory which allows users to search by physician first name, last name, city, state, and specialty to find ASAM certified providers.

This document explains the science behind drug abuse and addiction and provides information on effective approaches to treatment and recovery.

An introduction of the human brain, with descriptions of how the brain communicates, and how drugs work in the brain.

This powerpoint presentation of the treatment of acute and chronic pain patients presents several different aspects of pain care, including general points regarding pain treatments, acute pain in buprenorphine maintained patients, and the differences between acute and chronic pain.

A comprehensive PDF from CSAM that contains 1) the Drug Abuse Screening Test (DAST-10), 2) the Skinner Trauma History, 3) the CAGE questionnaire, 4) the TWEAK questionnaire, 5) the Alcohol Use Disorder Identification Test (AUDIT), 6) the Michigan Alcoholism Screening Test (MAST), 7) the Self-Administered Short Michigan Alcoholism Screening Test (SMAST), 8) Narcotic Withdrawal Scale, 9) the Clinical Institute Narcotic Assessment (CINA) Scale for Withdrawal, 10) the Clinical Opiate Withdrawal Scale (COWS), 11) the Objective Opiate Withdrawal Scale (OOWS), 12) the Subjective Opiate Withdrawal Scale (SOWS), and 13) the Addiction Research Foundation Clinical Institute for Withdrawal Assessment (CIWA-Ar). (From Their Website)

The Center for Substance Abuse Treatment (CSAT) promotes the quality and availability of community-based substance abuse treatment services for individuals and families who need them. CSAT works with States and community-based groups to improve and expand existing substance abuse treatment services under the Substance Abuse Prevention and Treatment Block Grant Program. CSAT also supports SAMHSA’s free treatment referral service to link people with the community-based substance abuse services they need (From their Website).

The American Psychiatric Association has released practice guidelines and resources for the treatment of patients with substance use disorders.

This three-minute video follows a young woman reflecting on her past dependence on heroin (follows a brief sponsored ad).

This is the website for the drug Intron A®, one of the five types of antiviral drugs approved to treat individuals with chronic hepatitis B.

This Treatment Improvement Protocol (TIP), Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction, provides consensus‐ and evidence‐based treatment guidance for the use of buprenorphine, a new option for the treatment of opioid addiction. The goal of this TIP is to provide physicians with information they can use to make practical and informed decisions about the use of buprenorphine to treat opioid addiction. These guidelines address the pharmacology and physiology of opioids, opioid addiction, and treatment with buprenorphine; describe patient assessment and the choice of opioid addiction treatment options; provide detailed treatment protocols for opioid withdrawal and maintenance therapy with buprenorphine; and include information on the treatment of special populations, e.g., pregnant women, adolescents, and polysubstance users. This TIP represents another step by the Center for Substance Abuse Treatment (CSAT) toward its goal of bringing national leaders together to improve substance use disorder treatment in the United States. (From Their Website)